Postprostatectomy radiotherapy for prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 5, 2009, Pages 529-534

  Mendenhall, William M ^a,b   Henderson, Randal H ^b   Nichols, R Charles ^b   Keole, Sameer R ^b   Mendenhall, Nancy P ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Post prostatectomy; Prostate cancer; Radiotherapy

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BLEEDING; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CYSTITIS; DIAGNOSTIC ACCURACY; DIARRHEA; DISTANT METASTASIS; HEMATURIA; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE FRACTIONATION; RECTUM DISEASE; RECTUM HEMORRHAGE; RECURRENT CANCER; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; TENESMUS; TREATMENT OUTCOME; URETHRA STRICTURE; URINE INCONTINENCE; UROGENITAL TRACT DISEASE;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; SURVIVAL RATE;

EID: 70350662206     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31817e6ef9     Document Type: Review

References (30)

1. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329-2335.
2. Ward JF, Zincke H, Bergstralh EJ, et al. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004; 172:1328-1332.
3. Bott SR, Freeman AA, Stenning S, et al. Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time. BJU Int. 2005;95:34-39.
4. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572-578.
5. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51:1175-1184.
6. Stockdale AD, Vakkalanka BK, Fahmy A, et al. Management of biochemical failure following radical prostatectomy: salvage radiotherapy-a case series. Prostate Cancer Prostatic Dis. 2007;10:205-209.
7. Jacinto AA, Fede AB, Fagundes LA, et al. Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy. Radiat Oncol. 2007;2:8.
8. Macdonald OK, D'Amico AV, Sadetsky N, et al. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database. Urology. 2007;70:106-110.
9. Johnstone PA, Assikis V, Goodman M, et al. Lack of survival benefit of post-operative radiation therapy in prostate cancer patients with positive lymph nodes. Prostate Cancer Prostatic Dis. 2007;10:185-188.
10. Wiltshire KL, Brock KK, Haider MA, et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;69:1090-1099.
11. Miralbell R, Vees H, Lozano J, et al. Endorectal MRI assessment of local relapse after surgery for prostate cancer: A model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys. 2007;67:356-361.
12. Pinkawa M, Siluschek J, Gagel B, et al. Postoperative radiotherapy for prostate cancer: Evaluation of target motion and treatment techniques (intensity- modulated versus conformal radiotherapy). Strahlenther Onkol. 2007; 183:23-29.
13. Schiffner DC, Gottschalk AR, Lometti M, et al. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;67:610-619.
14. Greco C, Castiglioni S, Fodor A, et al. Benefit on biochemical control of adjuvant radiation therapy in patients with pathologically involved seminal vesicles after radical prostatectomy. Tumori. 2007;93:445-451.
15. American Joint Committee on Cancer. AJCC Cancer Staging Handbook. 6th ed. New York, NY: Springer-Verlag; 2002:215.
16. Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25:2225-2229.
17. Moinpour CM, Hayden KA, Unger JM, et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol. 2008;26:112-120.
18. Van der Kwast TH, Bolla M, van Poppel H, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007;25:4178-4186.
19. Nagda SN, Mohideen N, Lo SS, et al. Long-term follow-up of 111incapromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:834-840.
20. Koontz BF, Mouraviev V, Johnson JL, et al. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;71:358-361.
21. Liauw SL, Weichselbaum RR, Zagaja GP, et al. Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease? Int J Radiat Oncol Biol Phys. In press.
22. Sciarra A, Panebianco V, Salciccia S, et al. Role of dynamic contrastenhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. 2007. In press.
23. Neuhof D, Hentschel T, Bischof M, et al. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys. 2007;67:1411-1417.
24. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325-1332.
25. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035-2041.
26. King CR, Presti JC, Brooks JD, et al. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2007;70:1472-1477.
27. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys. 2007;69:54-61.
28. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2008;71:23-27.
29. King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys. 2008;71:346-350.
30. Feng M, Hanlon AL, Pisansky TM, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 68:1417-1423.